Pharmaceutical preparations Stocks List

This page shows information about the 50 largest pharmaceutical preparations industry stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie, and Novo Nordisk A/S.

1. Eli Lilly and Company NYSE:LLY

$821.58 -2.48 (-0.30%)

As of 03:33 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

The company recently announced a stock buyback program worth $15 billion, indicating management's belief that the stock is undervalued, which can enhance shareholder value.
Eli Lilly and Co has a strong return on equity of 85.24%, suggesting effective management and profitability, which can attract investors looking for solid financial performance.
The latest quarterly earnings report showed earnings per share of $5.32, with analysts forecasting an EPS of 23.48 for the current fiscal year, indicating potential growth in profitability.

Cons of Eli Lilly and Company

The company missed its earnings consensus estimate by $0.13 in the latest quarter, which may raise concerns about its ability to meet future expectations.
With a debt-to-equity ratio of 2.00, Eli Lilly and Co has a relatively high level of debt compared to equity, which could pose risks in times of economic downturns.
The quick ratio of 0.97 indicates that the company may have difficulty covering its short-term liabilities, which could affect liquidity and operational flexibility.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $778.38 billion
P/E Ratio: 70.11
Consensus Rating: Moderate Buy
Consensus Price Target: $1,009.72 (+22.9% Upside)
Volume: 2.16 million shares
Average Volume: 3.12 million shares
Today's Range: $813.26
▼
$834.65
50-Day Range: $726.24
▼
$930.22
52-Week Range: $711.40
▼
$972.53
Dividend Yield: 0.69%

2. Johnson & Johnson NYSE:JNJ

$162.77 -3.09 (-1.86%)

As of 03:33 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

Johnson & Johnson has a strong market capitalization of $397.81 billion, indicating its stability and ability to weather market fluctuations.
The company recently reported a quarterly earnings per share (EPS) of $2.04, surpassing the consensus estimate of $1.99, which reflects its strong financial performance.
With a current stock price around $150.90, it is trading near its 50-day moving average, suggesting potential for upward movement as it aligns with market trends.

Cons of Johnson & Johnson

Analysts have recently adjusted their price targets downward, with Stifel Nicolaus lowering their target from $170.00 to $155.00, which may indicate concerns about future performance.
The company's price-to-earnings (P/E) ratio of 24.85 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
Johnson & Johnson's payout ratio is 74.59%, indicating that a significant portion of its earnings is being distributed as dividends, which may limit funds available for reinvestment in growth opportunities.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $391.90 billion
P/E Ratio: 24.48
Consensus Rating: Moderate Buy
Consensus Price Target: $171.33 (+5.3% Upside)
Volume: 4.93 million shares
Average Volume: 7.08 million shares
Today's Range: $162.23
▼
$164.21
50-Day Range: $142.07
▼
$167.57
52-Week Range: $140.68
▼
$169.99
Dividend Yield: 2.98%

3. AbbVie NYSE:ABBV

$212.29 -1.30 (-0.61%)

As of 03:33 PM Eastern

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

AbbVie has a strong dividend yield of 3.14%, with a quarterly dividend of $1.64, providing a steady income stream for investors.
The stock has received multiple upgrades from analysts, with a current average target price of $208.35, indicating potential for price appreciation.
AbbVie’s recent product offerings, including Rinvoq and Skyrizi, are positioned to address significant market needs in autoimmune diseases, enhancing revenue growth prospects.

Cons of AbbVie

The company has a high payout ratio of 273.33%, which may raise concerns about the sustainability of its dividend payments in the long term.
Insider selling has occurred, with a total of 56,439 shares sold recently, which could indicate a lack of confidence among company executives.
AbbVie faces significant competition in the pharmaceutical market, particularly in the areas of autoimmune and oncology treatments, which could impact market share and profitability.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $375.55 billion
P/E Ratio: 88.64
Consensus Rating: Moderate Buy
Consensus Price Target: $211.45 (-0.4% Downside)
Volume: 3.92 million shares
Average Volume: 6.11 million shares
Today's Range: $209.31
▼
$213.87
50-Day Range: $169.19
▼
$216.62
52-Week Range: $153.58
▼
$218.66
Dividend Yield: 3.11%

4. Novo Nordisk A/S NYSE:NVO

$74.80 -3.31 (-4.24%)

As of 03:33 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

Recent earnings report showed a strong performance with an EPS of $0.91, exceeding expectations, indicating robust financial health.
The company has a high return on equity of 84.68%, suggesting effective management and profitability, which can attract investors looking for strong returns.
With a current stock price of $89.76, analysts have set an average target price of $145.25, indicating significant upside potential for investors.

Cons of Novo Nordisk A/S

The stock has experienced a decline in trading volume, with a 73% drop from its average daily volume, which may indicate reduced investor interest.
Despite strong earnings, the stock has been trading near a 52-week low, which could signal underlying issues or market concerns.
Market analysts have mixed opinions, with some downgrading ratings, which could create uncertainty for potential investors.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $335.20 billion
P/E Ratio: 22.70
Consensus Rating: Moderate Buy
Consensus Price Target: $145.25 (+94.2% Upside)
Volume: 8.56 million shares
Average Volume: 5.37 million shares
Today's Range: $73.80
▼
$75.34
50-Day Range: $77.94
▼
$90.94
52-Week Range: $73.28
▼
$148.15
Dividend Yield: 0.82%

5. Merck & Co., Inc. NYSE:MRK

$93.31 -1.42 (-1.50%)

As of 03:33 PM Eastern

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

Merck's recent quarterly earnings report showed a revenue increase of 6.8% year-over-year, indicating strong business performance and growth potential.
The company has a solid net margin of 26.67% and a return on equity of 45.35%, reflecting efficient management and profitability, which are attractive to investors.
Merck's current stock price is $92.23, which is a reasonable entry point considering the company's market cap of $232.98 billion and a price-to-earnings ratio of 13.70, suggesting it may be undervalued compared to its earnings.

Cons of Merck & Co., Inc.

Analysts have recently lowered their earnings per share estimates for Q2 2025 from $2.42 to $2.19, indicating potential challenges in meeting growth expectations.
Merck's stock has seen a decline from its 1-year high of $134.63, which may raise concerns about its current valuation and future performance.
Several analysts have downgraded their ratings on Merck, with some moving from "buy" to "hold," suggesting a lack of confidence in the stock's short-term prospects.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $235.92 billion
P/E Ratio: 13.88
Consensus Rating: Moderate Buy
Consensus Price Target: $117.12 (+25.5% Upside)
Volume: 7.24 million shares
Average Volume: 10.09 million shares
Today's Range: $92.86
▼
$94.40
50-Day Range: $83.01
▼
$101.03
52-Week Range: $81.04
▼
$134.63
Dividend Yield: 3.45%

Remove Ads

6. AstraZeneca NASDAQ:AZN

$75.47 +1.23 (+1.66%)

As of 03:33 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

AstraZeneca has recently increased its semi-annual dividend to $1.03, up from $0.49, indicating strong financial health and a commitment to returning value to shareholders.
The current stock price is $76.08, which is within a range that reflects a solid market capitalization of approximately $236 billion, suggesting stability and growth potential.
The company reported a return on equity of 32.23%, which indicates effective management and profitability relative to shareholder equity, making it an attractive investment.

Cons of AstraZeneca

The company recently reported an EPS of $1.05, missing the consensus estimate of $1.10, which may raise concerns about its ability to meet market expectations.
AstraZeneca's current ratio is 0.93, which is below 1, indicating that the company may have difficulty covering its short-term liabilities with its short-term assets.
The stock has a price-to-earnings (P/E) ratio of 34.17, which is relatively high, suggesting that the stock may be overvalued compared to its earnings, potentially deterring value investors.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $234.02 billion
P/E Ratio: 33.39
Consensus Rating: Buy
Consensus Price Target: $89.75 (+18.9% Upside)
Volume: 4.37 million shares
Average Volume: 5.67 million shares
Today's Range: $74.68
▼
$75.79
50-Day Range: $65.37
▼
$77.96
52-Week Range: $62.75
▼
$87.68
Dividend Yield: 2.66%

7. Abbott Laboratories NYSE:ABT

$130.30 -2.36 (-1.78%)

As of 03:33 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

Abbott Laboratories has demonstrated strong financial performance with a return on equity of 20.74%, indicating effective management and profitability relative to shareholder equity.
The company reported a net margin of 31.95%, showcasing its ability to convert revenue into profit efficiently, which is attractive for investors seeking stable returns.
Recent revenue growth of 7.2% compared to the same quarter last year reflects Abbott Laboratories' resilience and ability to expand its market presence, which can lead to increased shareholder value.

Cons of Abbott Laboratories

Despite strong financial metrics, the company fell short of revenue expectations with $10.97 billion against a consensus estimate of $11.03 billion, which may raise concerns about future growth potential.
Insider selling activity, such as the recent sale of 23,771 shares by an executive vice president, could signal a lack of confidence in the stock's short-term performance, which may deter potential investors.
The stock has experienced volatility, recently trading down 1.8%, which could indicate market uncertainty and affect investor sentiment negatively.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $226.03 billion
P/E Ratio: 17.04
Consensus Rating: Moderate Buy
Consensus Price Target: $137.94 (+5.9% Upside)
Volume: 4.64 million shares
Average Volume: 5.55 million shares
Today's Range: $129.44
▼
$132.61
50-Day Range: $110.96
▼
$140.13
52-Week Range: $99.71
▼
$141.23
Dividend Yield: 1.72%

8. Novartis NYSE:NVS

$108.52 +1.04 (+0.97%)

As of 03:33 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

Novartis AG recently reported earnings per share of $1.98, surpassing analysts' expectations of $1.80, indicating strong financial performance and effective management.
The current stock price is $109.06, which reflects a stable market position and potential for growth, especially considering the company's market capitalization of $222.91 billion.
Analysts have recently upgraded Novartis AG's rating, with StockNews.com moving it from a "buy" to a "strong-buy," suggesting increased confidence in the company's future performance.

Cons of Novartis

Despite recent upgrades, some analysts maintain a "sell" or "underweight" rating on Novartis AG, reflecting concerns about its long-term growth potential.
HSBC recently downgraded Novartis AG from a "hold" to a "reduce" rating, which may indicate potential challenges in the company's market performance.
The company has a debt-to-equity ratio of 0.48, which, while not excessively high, suggests that it is somewhat reliant on debt financing, potentially increasing financial risk.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $221.79 billion
P/E Ratio: 18.45
Consensus Rating: Reduce
Consensus Price Target: $123.38 (+13.7% Upside)
Volume: 1.90 million shares
Average Volume: 2.06 million shares
Today's Range: $108.44
▼
$109.25
50-Day Range: $97.14
▼
$115.60
52-Week Range: $92.35
▼
$120.92
Dividend Yield: 2.15%

9. Sanofi NASDAQ:SNY

$57.70 -1.04 (-1.77%)

As of 03:33 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

Sanofi has a strong market capitalization of $138.21 billion, indicating a robust financial position and potential for growth.
The company reported earnings per share (EPS) of $0.70, meeting analysts' expectations, which reflects stability in its earnings performance.
Recent upgrades from analysts, including a "strong-buy" rating from Sanford C. Bernstein, suggest positive sentiment and confidence in the company's future performance.

Cons of Sanofi

Despite a solid EPS, the company's net margin of 12.77% may be lower than some competitors, potentially limiting profitability growth.
Analysts have issued mixed ratings, with some maintaining a "hold" rating, indicating uncertainty about the stock's future performance.
Sanofi's stock has a beta of 0.57, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-growth opportunities.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $146.48 billion
P/E Ratio: 23.18
Consensus Rating: Buy
Consensus Price Target: $60.00 (+4.0% Upside)
Volume: 2.22 million shares
Average Volume: 2.21 million shares
Today's Range: $57.44
▼
$58.07
50-Day Range: $48.15
▼
$59.42
52-Week Range: $45.22
▼
$60.12
Dividend Yield: 2.49%

10. Pfizer NYSE:PFE

$25.76 -0.23 (-0.90%)

As of 03:33 PM Eastern

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

Pfizer Inc. reported a quarterly EPS of $0.63, exceeding the consensus estimate of $0.48 by $0.15, indicating strong financial performance and effective cost management.
The company experienced a significant year-over-year revenue increase of 24.7%, reaching $17.76 billion, which reflects robust demand for its biopharmaceutical products.
Pfizer Inc. has announced a quarterly dividend of $0.43 per share, up from $0.42, providing a reliable income stream for investors with a yield of 6.56%.

Cons of Pfizer

Despite strong earnings, some analysts have issued "underperform" ratings, indicating potential concerns about the stock's future performance.
The dividend payout ratio is 121.99%, which means the company is paying out more in dividends than it earns, raising concerns about sustainability.
Several analysts have lowered their price targets for Pfizer Inc., with some setting targets as low as $25.00, which may indicate a lack of confidence in future growth.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $146.02 billion
P/E Ratio: 18.27
Consensus Rating: Moderate Buy
Consensus Price Target: $31.92 (+23.9% Upside)
Volume: 26.04 million shares
Average Volume: 39.86 million shares
Today's Range: $25.50
▼
$25.97
50-Day Range: $25.46
▼
$27.12
52-Week Range: $24.48
▼
$31.54
Dividend Yield: 6.55%

Remove Ads

11. Vertex Pharmaceuticals NASDAQ:VRTX

$495.06 +6.72 (+1.38%)

As of 03:33 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

Vertex Pharmaceuticals has a strong market capitalization of $123.21 billion, indicating a robust financial position and potential for growth.
The stock recently traded at $479.79, reflecting a 1.1% increase, which may suggest positive market sentiment and potential for further appreciation.
Analysts have a consensus rating of "Moderate Buy" with a target price of $506.70, indicating that many believe the stock is undervalued and has room for growth.

Cons of Vertex Pharmaceuticals

Vertex Pharmaceuticals reported earnings per share (EPS) of $3.54, missing analysts' expectations of $3.99, which may raise concerns about the company's short-term profitability.
The company has a negative return on equity of 2.02% and a negative net margin of 4.86%, indicating challenges in generating profit relative to shareholder equity and overall sales.
Insider selling of 1,084 shares valued at $505,512 in the last quarter could signal a lack of confidence from those within the company.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $127.22 billion
P/E Ratio: -225.19
Consensus Rating: Moderate Buy
Consensus Price Target: $506.70 (+2.4% Upside)
Volume: 776,146 shares
Average Volume: 1.47 million shares
Today's Range: $483.09
▼
$496.64
50-Day Range: $402.49
▼
$500.01
52-Week Range: $377.85
▼
$519.88
Dividend Yield: N/A

12. Bristol-Myers Squibb NYSE:BMY

$60.01 -1.50 (-2.44%)

As of 03:33 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol-Myers Squibb

Pros of Bristol-Myers Squibb

The stock currently has a consensus rating of "Hold" with an average price target of $57.86, indicating potential for price appreciation.
Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive revenue growth.
Recent insider buying activity, such as the purchase of 1,823 shares by EVP Samit Hirawat, suggests confidence in the company's future performance.

Cons of Bristol-Myers Squibb

Despite the positive outlook, the stock's "Hold" rating may indicate that significant upside is limited in the near term, suggesting caution for potential investors.
Insider ownership is relatively low at 0.09%, which may raise concerns about alignment between management and shareholder interests.
The pharmaceutical industry is highly competitive, and Bristol-Myers Squibb faces challenges from generic drugs and other companies developing similar therapies.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $121.50 billion
P/E Ratio: -13.55
Consensus Rating: Hold
Consensus Price Target: $57.86 (-3.6% Downside)
Volume: 7.35 million shares
Average Volume: 11.59 million shares
Today's Range: $59.52
▼
$60.82
50-Day Range: $53.85
▼
$63.00
52-Week Range: $39.35
▼
$63.33
Dividend Yield: 4.06%

13. GSK NYSE:GSK

$38.88 -0.62 (-1.56%)

As of 03:33 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

GSK plc recently reported earnings per share (EPS) of $0.59, exceeding the consensus estimate of $0.44, indicating strong financial performance and potential for growth.
The stock is currently trading at $40.08, which reflects a positive trend and may attract investors looking for growth opportunities.
GSK plc has increased its quarterly dividend to $0.3932, up from $0.39, demonstrating a commitment to returning value to shareholders and indicating financial health.

Cons of GSK

Deutsche Bank recently downgraded GSK plc from a "buy" rating to a "hold" rating, indicating a more cautious outlook from analysts.
The stock has a relatively high price-to-earnings (P/E) ratio of 25.21, which may suggest that it is overvalued compared to its earnings potential.
GSK plc has a debt-to-equity ratio of 1.12, indicating that the company has a significant amount of debt compared to its equity, which could pose risks in a rising interest rate environment.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $80.52 billion
P/E Ratio: 24.43
Consensus Rating: Moderate Buy
Consensus Price Target: $43.25 (+11.2% Upside)
Volume: 4.30 million shares
Average Volume: 4.27 million shares
Today's Range: $38.78
▼
$39.32
50-Day Range: $32.12
▼
$40.41
52-Week Range: $31.72
▼
$45.93
Dividend Yield: 4.00%

14. Regeneron Pharmaceuticals NASDAQ:REGN

$691.32 -26.84 (-3.74%)

As of 03:33 PM Eastern

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. reported a strong quarterly earnings result with an earnings per share (EPS) of $12.07, exceeding analysts' expectations of $11.21, indicating robust financial performance.
The company has a solid market capitalization of approximately $78.42 billion, reflecting its significant presence and stability in the biopharmaceutical sector.
With a current ratio of 4.73, Regeneron Pharmaceuticals, Inc. demonstrates strong liquidity, meaning it has ample short-term assets to cover its liabilities, which is a positive sign for investors.

Cons of Regeneron Pharmaceuticals

The stock has experienced a decline, trading down $26.67 recently, which may indicate volatility and potential risks for investors.
Analysts have mixed ratings on the stock, with one sell rating and several hold ratings, suggesting uncertainty about its future performance.
The PEG ratio of 2.34 indicates that the stock may be overvalued relative to its earnings growth, which could deter value-focused investors.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $75.68 billion
P/E Ratio: 18.08
Consensus Rating: Moderate Buy
Consensus Price Target: $973.13 (+40.8% Upside)
Volume: 580,823 shares
Average Volume: 620,095 shares
Today's Range: $683.43
▼
$712.46
50-Day Range: $663.86
▼
$744.83
52-Week Range: $642.00
▼
$1,211.20
Dividend Yield: 0.12%

15. Zoetis NYSE:ZTS

$162.23 -2.16 (-1.31%)

As of 03:33 PM Eastern

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

Zoetis Inc. has shown strong financial performance, with a recent earnings report indicating an EPS of $1.40, surpassing the consensus estimate of $1.37. This suggests robust profitability and effective management.
The stock is currently trading at $166.18, which is near its 52-week high of $200.33, indicating strong market confidence and potential for growth.
Institutional ownership is high at 92.80%, reflecting strong confidence from large investors, which can be a positive indicator for retail investors.

Cons of Zoetis

PNC Financial Services Group Inc. recently reduced its position in Zoetis Inc. by 5.8%, which may signal concerns about the stock's future performance among institutional investors.
The stock has experienced volatility, with a recent drop of $5.62 during trading hours, indicating potential instability that could deter risk-averse investors.
Despite strong earnings, the price-to-earnings ratio of 30.05 suggests that the stock may be overvalued compared to its earnings, which could lead to a correction.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $72.74 billion
P/E Ratio: 29.70
Consensus Rating: Buy
Consensus Price Target: $215.90 (+33.1% Upside)
Volume: 1.62 million shares
Average Volume: 2.57 million shares
Today's Range: $160.52
▼
$163.99
50-Day Range: $156.43
▼
$175.65
52-Week Range: $144.80
▼
$200.33
Dividend Yield: 1.20%

Remove Ads

16. Takeda Pharmaceutical NYSE:TAK

$14.92 +0.03 (+0.17%)

As of 03:33 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited recently reached a new 52-week high of $15.08, indicating strong market performance and investor confidence.
The company reported a quarterly earnings per share (EPS) of $0.42, surpassing analysts' expectations of $0.34, which reflects effective management and operational efficiency.
With a market capitalization of approximately $48.29 billion, Takeda Pharmaceutical Company Limited is positioned as a significant player in the pharmaceutical industry, suggesting stability and growth potential.

Cons of Takeda Pharmaceutical

The stock has a relatively high price-to-earnings (P/E) ratio of 37.94, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
Despite recent gains, the stock's beta of 0.46 suggests lower volatility compared to the market, which may limit potential high returns for aggressive investors.
Takeda Pharmaceutical Company Limited has a net margin of only 4.53%, which may indicate challenges in maintaining profitability compared to competitors.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $47.49 billion
P/E Ratio: 37.31
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 1.19 million shares
Average Volume: 1.81 million shares
Today's Range: $14.84
▼
$14.96
50-Day Range: $12.91
▼
$15.18
52-Week Range: $12.57
▼
$15.22
Dividend Yield: 3.56%

17. Alnylam Pharmaceuticals NASDAQ:ALNY

$244.44 +5.71 (+2.39%)

As of 03:33 PM Eastern

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

Recent positive forecast from HC Wainwright, raising the price target from $400.00 to $500.00, indicating strong growth potential.
Current stock price is $237.18, which is significantly lower than the recent high of $304.39, suggesting a potential buying opportunity for investors looking for value.
Analysts have a consensus rating of "Moderate Buy" with an average price target of $304.26, reflecting overall confidence in the company's future performance.

Cons of Alnylam Pharmaceuticals

Insider selling of 72,986 shares valued at over $20 million raises concerns about the confidence of current management in the company's future.
Recent earnings report showed a loss of ($0.65) EPS, missing the consensus estimate, which may indicate operational challenges.
Some analysts have downgraded their ratings, with Wolfe Research moving from "peer perform" to "underperform," suggesting potential weaknesses in the stock's performance.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $31.66 billion
P/E Ratio: -112.70
Consensus Rating: Moderate Buy
Consensus Price Target: $304.26 (+24.5% Upside)
Volume: 394,950 shares
Average Volume: 789,617 shares
Today's Range: $240.39
▼
$246.37
50-Day Range: $233.07
▼
$278.99
52-Week Range: $141.98
▼
$304.39
Dividend Yield: N/A

18. Beigene NASDAQ:ONC

$249.41 +3.70 (+1.51%)

As of 03:16 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Market Capitalization: $24.41 billion
P/E Ratio: -30.27
Consensus Rating: Buy
Consensus Price Target: $327.00 (+31.1% Upside)
Volume: 240,412 shares
Average Volume: 455,509 shares
Today's Range: $244.08
▼
$249.50
50-Day Range: $0.00
▼
$0.00
52-Week Range: $126.97
▼
$287.88
Dividend Yield: N/A

19. Royalty Pharma NASDAQ:RPRX

$32.78 +0.33 (+1.00%)

As of 03:33 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

The stock is currently priced at $33.64, reflecting a stable market position and potential for growth.
Royalty Pharma plc has recently increased its quarterly dividend from $0.21 to $0.22, indicating a commitment to returning value to shareholders.
Analysts have a consensus price target of $41.60, suggesting significant upside potential from the current stock price.

Cons of Royalty Pharma

The stock has a relatively low beta of 0.49, which may indicate lower volatility but also less potential for rapid gains compared to higher beta stocks.
Despite recent positive developments, the stock has seen fluctuations, with a 12-month low of $24.05, which may raise concerns about stability.
The price-to-earnings ratio of 23.20 may suggest that the stock is overvalued compared to its earnings, which could deter value-focused investors.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $18.92 billion
P/E Ratio: 22.63
Consensus Rating: Buy
Consensus Price Target: $41.60 (+26.9% Upside)
Volume: 2.16 million shares
Average Volume: 2.82 million shares
Today's Range: $32.00
▼
$32.92
50-Day Range: $25.51
▼
$33.86
52-Week Range: $24.05
▼
$34.20
Dividend Yield: 2.64%

20. Teva Pharmaceutical Industries NYSE:TEVA

$16.68 +0.58 (+3.57%)

As of 03:33 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization: $18.88 billion
P/E Ratio: -11.49
Consensus Rating: Moderate Buy
Consensus Price Target: $23.43 (+40.5% Upside)
Volume: 9.78 million shares
Average Volume: 12.90 million shares
Today's Range: $16.05
▼
$16.66
50-Day Range: $14.69
▼
$22.04
52-Week Range: $12.51
▼
$22.80
Dividend Yield: N/A

Remove Ads

21. Summit Therapeutics NASDAQ:SMMT

$20.07 +1.57 (+8.51%)

As of 03:33 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Market Capitalization: $14.77 billion
P/E Ratio: -71.51
Consensus Rating: Moderate Buy
Consensus Price Target: $34.11 (+69.9% Upside)
Volume: 2.14 million shares
Average Volume: 2.52 million shares
Today's Range: $19.28
▼
$20.50
50-Day Range: $16.65
▼
$24.65
52-Week Range: $2.10
▼
$33.89
Dividend Yield: N/A

22. Intra-Cellular Therapies NASDAQ:ITCI

$131.24 -0.01 (0.00%)

As of 03:33 PM Eastern

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Market Capitalization: $13.95 billion
P/E Ratio: -150.83
Consensus Rating: Hold
Consensus Price Target: $106.08 (-19.2% Downside)
Volume: 2.29 million shares
Average Volume: 1.31 million shares
Today's Range: $131.19
▼
$131.33
50-Day Range: $81.78
▼
$131.28
52-Week Range: $63.30
▼
$131.37
Dividend Yield: N/A

23. United Therapeutics NASDAQ:UTHR

$305.62 +1.20 (+0.39%)

As of 03:33 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Market Capitalization: $13.74 billion
P/E Ratio: 13.44
Consensus Rating: Moderate Buy
Consensus Price Target: $388.25 (+27.0% Upside)
Volume: 266,804 shares
Average Volume: 444,164 shares
Today's Range: $301.25
▼
$307.14
50-Day Range: $304.42
▼
$380.78
52-Week Range: $221.53
▼
$417.82
Dividend Yield: N/A

24. Insmed NASDAQ:INSM

$74.82 +1.12 (+1.52%)

As of 03:33 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Market Capitalization: $13.55 billion
P/E Ratio: -13.39
Consensus Rating: Buy
Consensus Price Target: $93.33 (+24.7% Upside)
Volume: 790,366 shares
Average Volume: 1.96 million shares
Today's Range: $74.04
▼
$76.31
50-Day Range: $65.25
▼
$83.83
52-Week Range: $21.92
▼
$84.91
Dividend Yield: N/A

25. Genmab A/S NASDAQ:GMAB

$20.27 +0.01 (+0.03%)

As of 03:33 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. More about Genmab A/S

Pros of Genmab A/S

Genmab A/S recently reported earnings per share of $0.57, significantly exceeding the consensus estimate of $0.28, indicating strong financial performance and effective management.
The stock is currently trading at $22.44, reflecting a positive trend in its market performance, which may attract more investors looking for growth opportunities.
Analysts have a consensus price target of $42.17, suggesting substantial upside potential from the current trading price, which could lead to significant returns for investors.

Cons of Genmab A/S

The stock has a relatively high price-to-earnings (P/E) ratio of 12.90, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
Despite recent positive earnings, the company has a P/E/G ratio of 2.57, suggesting that its growth may not justify its current valuation, which could deter value-focused investors.
Genmab A/S has experienced significant price fluctuations, with a 52-week high of $31.88 and a low of $18.64, indicating volatility that may pose risks for investors seeking stability.

A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Market Capitalization: $13.45 billion
P/E Ratio: 11.68
Consensus Rating: Moderate Buy
Consensus Price Target: $41.33 (+103.9% Upside)
Volume: 1.29 million shares
Average Volume: 895,553 shares
Today's Range: $20.07
▼
$20.36
50-Day Range: $18.69
▼
$24.14
52-Week Range: $18.64
▼
$31.88
Dividend Yield: N/A

Remove Ads

26. BioMarin Pharmaceutical NASDAQ:BMRN

$70.48 -0.01 (-0.01%)

As of 03:33 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Market Capitalization: $13.45 billion
P/E Ratio: 32.04
Consensus Rating: Moderate Buy
Consensus Price Target: $94.00 (+33.4% Upside)
Volume: 570,340 shares
Average Volume: 1.77 million shares
Today's Range: $69.64
▼
$70.82
50-Day Range: $61.25
▼
$72.23
52-Week Range: $60.63
▼
$94.85
Dividend Yield: N/A

27. Viatris NASDAQ:VTRS

$9.32 -0.03 (-0.27%)

As of 03:33 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Market Capitalization: $11.12 billion
P/E Ratio: -12.59
Consensus Rating: Reduce
Consensus Price Target: $10.50 (+12.7% Upside)
Volume: 6.26 million shares
Average Volume: 8.48 million shares
Today's Range: $9.23
▼
$9.47
50-Day Range: $9.23
▼
$12.45
52-Week Range: $8.77
▼
$13.55
Dividend Yield: 5.05%

28. Dr. Reddy's Laboratories NYSE:RDY

$12.54 -0.18 (-1.38%)

As of 03:33 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Market Capitalization: $10.46 billion
P/E Ratio: 19.96
Consensus Rating: Moderate Buy
Consensus Price Target: $17.00 (+35.6% Upside)
Volume: 750,147 shares
Average Volume: 1.24 million shares
Today's Range: $12.50
▼
$12.67
50-Day Range: $12.70
▼
$15.81
52-Week Range: $12.51
▼
$16.89
Dividend Yield: 0.62%

29. Sarepta Therapeutics NASDAQ:SRPT

$99.47 -1.24 (-1.23%)

As of 03:33 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Market Capitalization: $9.66 billion
P/E Ratio: 79.64
Consensus Rating: Moderate Buy
Consensus Price Target: $170.41 (+71.3% Upside)
Volume: 321,975 shares
Average Volume: 911,730 shares
Today's Range: $99.09
▼
$102.40
50-Day Range: $99.69
▼
$127.89
52-Week Range: $97.91
▼
$173.25
Dividend Yield: N/A

30. Ascendis Pharma A/S NASDAQ:ASND

$148.78 +3.15 (+2.16%)

As of 03:33 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Market Capitalization: $9.02 billion
P/E Ratio: -20.94
Consensus Rating: Moderate Buy
Consensus Price Target: $202.36 (+36.0% Upside)
Volume: 256,752 shares
Average Volume: 453,257 shares
Today's Range: $146.05
▼
$150.61
50-Day Range: $119.49
▼
$157.17
52-Week Range: $111.09
▼
$158.00
Dividend Yield: N/A

Remove Ads

31. Jazz Pharmaceuticals NASDAQ:JAZZ

$134.31 -2.55 (-1.87%)

As of 03:33 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Market Capitalization: $8.15 billion
P/E Ratio: 18.90
Consensus Rating: Moderate Buy
Consensus Price Target: $190.53 (+41.9% Upside)
Volume: 429,064 shares
Average Volume: 769,044 shares
Today's Range: $134.16
▼
$137.51
50-Day Range: $120.07
▼
$144.17
52-Week Range: $99.06
▼
$148.06
Dividend Yield: N/A

32. Roivant Sciences NASDAQ:ROIV

$10.60 +0.06 (+0.52%)

As of 03:33 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Market Capitalization: $7.56 billion
P/E Ratio: -70.63
Consensus Rating: Buy
Consensus Price Target: $18.08 (+70.5% Upside)
Volume: 3.60 million shares
Average Volume: 4.46 million shares
Today's Range: $10.48
▼
$10.69
50-Day Range: $10.17
▼
$12.08
52-Week Range: $9.76
▼
$13.06
Dividend Yield: N/A

33. Madrigal Pharmaceuticals NASDAQ:MDGL

$327.52 -7.87 (-2.35%)

As of 03:33 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Market Capitalization: $7.21 billion
P/E Ratio: -13.01
Consensus Rating: Moderate Buy
Consensus Price Target: $375.75 (+14.7% Upside)
Volume: 353,714 shares
Average Volume: 436,954 shares
Today's Range: $322.41
▼
$344.17
50-Day Range: $272.79
▼
$355.88
52-Week Range: $189.00
▼
$377.46
Dividend Yield: N/A

34. Legend Biotech NASDAQ:LEGN

$38.12 +0.93 (+2.49%)

As of 03:33 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Market Capitalization: $6.95 billion
P/E Ratio: -40.07
Consensus Rating: Moderate Buy
Consensus Price Target: $79.67 (+109.0% Upside)
Volume: 804,471 shares
Average Volume: 1.18 million shares
Today's Range: $36.97
▼
$38.70
50-Day Range: $31.43
▼
$39.70
52-Week Range: $30.17
▼
$69.24
Dividend Yield: N/A

35. BridgeBio Pharma NASDAQ:BBIO

$32.62 +0.28 (+0.86%)

As of 03:33 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Market Capitalization: $6.19 billion
P/E Ratio: -11.43
Consensus Rating: Moderate Buy
Consensus Price Target: $51.55 (+58.0% Upside)
Volume: 1.24 million shares
Average Volume: 3.17 million shares
Today's Range: $32.39
▼
$33.19
50-Day Range: $27.44
▼
$37.59
52-Week Range: $21.62
▼
$39.47
Dividend Yield: N/A

Remove Ads

36. Axsome Therapeutics NASDAQ:AXSM

$120.77 +1.27 (+1.06%)

As of 03:33 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Market Capitalization: $5.89 billion
P/E Ratio: -20.17
Consensus Rating: Buy
Consensus Price Target: $167.36 (+38.6% Upside)
Volume: 302,228 shares
Average Volume: 653,329 shares
Today's Range: $118.73
▼
$122.51
50-Day Range: $80.05
▼
$137.75
52-Week Range: $64.11
▼
$139.13
Dividend Yield: N/A

37. TG Therapeutics NASDAQ:TGTX

$37.38 -0.17 (-0.45%)

As of 03:33 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Market Capitalization: $5.88 billion
P/E Ratio: -374.04
Consensus Rating: Moderate Buy
Consensus Price Target: $40.67 (+8.8% Upside)
Volume: 1.73 million shares
Average Volume: 2.62 million shares
Today's Range: $36.82
▼
$38.70
50-Day Range: $27.67
▼
$39.23
52-Week Range: $12.93
▼
$40.31
Dividend Yield: N/A

38. Corcept Therapeutics NASDAQ:CORT

$54.99 -0.43 (-0.78%)

As of 03:33 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Market Capitalization: $5.80 billion
P/E Ratio: 43.65
Consensus Rating: Buy
Consensus Price Target: $99.75 (+81.4% Upside)
Volume: 583,776 shares
Average Volume: 1.04 million shares
Today's Range: $54.40
▼
$57.95
50-Day Range: $49.85
▼
$73.61
52-Week Range: $20.84
▼
$75.00
Dividend Yield: N/A

39. Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX

$17.22 +0.47 (+2.81%)

As of 03:33 PM Eastern

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Market Capitalization: $5.80 billion
P/E Ratio: N/A
Consensus Rating: Buy
Consensus Price Target: $22.00 (+27.8% Upside)
Volume: 19,876 shares
Average Volume: 27,916 shares
Today's Range: $16.93
▼
$17.40
50-Day Range: $14.56
▼
$20.93
52-Week Range: $14.01
▼
$30.36
Dividend Yield: N/A

40. Blueprint Medicines NASDAQ:BPMC

$90.11 +2.35 (+2.68%)

As of 03:33 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Market Capitalization: $5.76 billion
P/E Ratio: -83.45
Consensus Rating: Moderate Buy
Consensus Price Target: $125.21 (+38.9% Upside)
Volume: 533,102 shares
Average Volume: 993,298 shares
Today's Range: $86.82
▼
$90.61
50-Day Range: $86.69
▼
$115.63
52-Week Range: $80.68
▼
$121.90
Dividend Yield: N/A

Remove Ads

41. Verona Pharma NASDAQ:VRNA

$67.93 +5.23 (+8.35%)

As of 03:33 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Market Capitalization: $5.50 billion
P/E Ratio: -35.46
Consensus Rating: Buy
Consensus Price Target: $69.14 (+1.8% Upside)
Volume: 1.04 million shares
Average Volume: 1.53 million shares
Today's Range: $63.94
▼
$68.60
50-Day Range: $44.81
▼
$69.63
52-Week Range: $11.39
▼
$70.40
Dividend Yield: N/A

42. Alkermes NASDAQ:ALKS

$33.45 -0.81 (-2.36%)

As of 03:33 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Market Capitalization: $5.44 billion
P/E Ratio: 15.42
Consensus Rating: Moderate Buy
Consensus Price Target: $38.33 (+14.6% Upside)
Volume: 751,141 shares
Average Volume: 1.74 million shares
Today's Range: $33.47
▼
$34.52
50-Day Range: $28.08
▼
$36.00
52-Week Range: $22.90
▼
$36.45
Dividend Yield: N/A

43. Grifols NASDAQ:GRFS

$7.84 +0.11 (+1.36%)

As of 03:32 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Market Capitalization: $5.39 billion
P/E Ratio: 6.70
Consensus Rating: Strong Buy
Consensus Price Target: N/A
Volume: 2.98 million shares
Average Volume: 1.30 million shares
Today's Range: $7.36
▼
$7.96
50-Day Range: $6.62
▼
$8.71
52-Week Range: $5.68
▼
$9.96
Dividend Yield: N/A

44. Ionis Pharmaceuticals NASDAQ:IONS

$33.81 +0.78 (+2.37%)

As of 03:33 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Market Capitalization: $5.37 billion
P/E Ratio: -11.12
Consensus Rating: Moderate Buy
Consensus Price Target: $59.56 (+76.1% Upside)
Volume: 881,904 shares
Average Volume: 1.66 million shares
Today's Range: $32.84
▼
$34.13
50-Day Range: $30.35
▼
$34.97
52-Week Range: $30.23
▼
$52.34
Dividend Yield: N/A

45. Nuvalent NASDAQ:NUVL

$72.54 +2.29 (+3.26%)

As of 03:33 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Market Capitalization: $5.21 billion
P/E Ratio: -20.99
Consensus Rating: Moderate Buy
Consensus Price Target: $113.10 (+55.9% Upside)
Volume: 419,114 shares
Average Volume: 459,515 shares
Today's Range: $69.50
▼
$73.28
50-Day Range: $67.38
▼
$88.96
52-Week Range: $61.80
▼
$113.51
Dividend Yield: N/A

Remove Ads

46. Cytokinetics NASDAQ:CYTK

$44.00 -0.40 (-0.91%)

As of 03:33 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Market Capitalization: $5.21 billion
P/E Ratio: -8.19
Consensus Rating: Moderate Buy
Consensus Price Target: $82.00 (+86.4% Upside)
Volume: 973,340 shares
Average Volume: 1.57 million shares
Today's Range: $43.55
▼
$45.07
50-Day Range: $41.56
▼
$51.12
52-Week Range: $40.53
▼
$75.71
Dividend Yield: N/A

47. Elanco Animal Health NYSE:ELAN

$10.40 +0.36 (+3.55%)

As of 03:33 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Market Capitalization: $5.14 billion
P/E Ratio: 25.99
Consensus Rating: Hold
Consensus Price Target: $15.17 (+45.9% Upside)
Volume: 2.72 million shares
Average Volume: 4.66 million shares
Today's Range: $10.10
▼
$10.42
50-Day Range: $10.07
▼
$12.47
52-Week Range: $10.03
▼
$18.80
Dividend Yield: N/A

48. PTC Therapeutics NASDAQ:PTCT

$53.41 +0.82 (+1.57%)

As of 03:33 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Market Capitalization: $4.21 billion
P/E Ratio: -8.99
Consensus Rating: Moderate Buy
Consensus Price Target: $63.54 (+19.0% Upside)
Volume: 289,056 shares
Average Volume: 739,727 shares
Today's Range: $52.26
▼
$53.54
50-Day Range: $41.81
▼
$55.26
52-Week Range: $24.00
▼
$55.60
Dividend Yield: N/A

49. Prestige Consumer Healthcare NYSE:PBH

$83.00 -2.09 (-2.46%)

As of 03:33 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Market Capitalization: $4.12 billion
P/E Ratio: 19.46
Consensus Rating: Moderate Buy
Consensus Price Target: $92.60 (+11.6% Upside)
Volume: 298,542 shares
Average Volume: 333,231 shares
Today's Range: $81.78
▼
$85.11
50-Day Range: $73.91
▼
$89.10
52-Week Range: $62.35
▼
$90.04
Dividend Yield: N/A

50. Avidity Biosciences NASDAQ:RNA

$32.15 +2.57 (+8.68%)

As of 03:33 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Market Capitalization: $3.88 billion
P/E Ratio: -11.21
Consensus Rating: Buy
Consensus Price Target: $66.42 (+106.6% Upside)
Volume: 747,895 shares
Average Volume: 1.32 million shares
Today's Range: $30.68
▼
$32.44
50-Day Range: $27.05
▼
$35.11
52-Week Range: $20.91
▼
$56.00
Dividend Yield: N/A

Remove Ads

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharmaceutical preparations Stocks List

Pros of Eli Lilly and Company

Cons of Eli Lilly and Company

Pros of Johnson & Johnson

Cons of Johnson & Johnson

Pros of AbbVie

Cons of AbbVie

Pros of Novo Nordisk A/S

Cons of Novo Nordisk A/S

Pros of Merck & Co., Inc.

Cons of Merck & Co., Inc.

Pros of AstraZeneca

Cons of AstraZeneca

Pros of Abbott Laboratories

Cons of Abbott Laboratories

Pros of Novartis

Cons of Novartis

Pros of Sanofi

Cons of Sanofi

Pros of Pfizer

Cons of Pfizer

Pros of Vertex Pharmaceuticals

Cons of Vertex Pharmaceuticals

Pros of Bristol-Myers Squibb

Cons of Bristol-Myers Squibb

Pros of GSK

Cons of GSK

Pros of Regeneron Pharmaceuticals

Cons of Regeneron Pharmaceuticals

Pros of Zoetis

Cons of Zoetis

Pros of Takeda Pharmaceutical

Cons of Takeda Pharmaceutical

Pros of Alnylam Pharmaceuticals

Cons of Alnylam Pharmaceuticals

Pros of Royalty Pharma

Cons of Royalty Pharma

Pros of Genmab A/S

Cons of Genmab A/S

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools